Advertisement

Inflammation Research

, Volume 65, Issue 2, pp 95–102 | Cite as

An evaluation of calprotectin as serum marker of preeclampsia: a systematic review of observational studies

  • Vasilios Pergialiotis
  • Anastasia Prodromidou
  • Eleni Pappa
  • Georgios D. Vlachos
  • Despina N. Perrea
  • Nikolaos Papantoniou
Review

Abstract

Background

Calprotectin is calcium-binding protein which can be found in the cytosol of neutrophils. Several studies have studied its levels in preeclamptic women; however, to date there is no consensus regarding its effectiveness in the field.

Purpose

To investigate whether serum calprotectin levels are elevated among preeclamptic women compared to healthy controls.

Materials and methods

We used Medline (1966–2015), Scopus (2004–2015), ClinicalTrials.gov (2008–2015), Cochrane Central Register of Controlled Trials CENTRAL (1999–2015) and Google Scholar (2004–2015) search engines in our primary search, together with reference lists from included studies.

Results

Seven studies were finally included in our systematic review which recruited 439 women (245 with preeclampsia and 194 healthy controls). Their methodological quality was relatively high as they reached a score that ranged between 6 and 7 according to the Ottawa–Newcastle classification. All included studies reported that the serum calprotectin levels were significantly elevated among preeclamptic patients (p < 0.05). One study suggested that patients with severe preeclampsia have significantly higher levels of calprotectin than patients with mild preeclampsia (p = 0.01). However, to date there is no evidence regarding specific cut-off values which would help screen women for preeclampsia, or even follow the course of the disease.

Conclusion

Current evidence suggests that serum calprotectin is significantly raised among women with preeclampsia during the third trimester. Future research is needed to reach firm conclusions regarding its use as a potential screening and surveillance marker during the pregnancy course of women at risk of developing preeclampsia.

Keywords

Calprotectin Pregnancy Preeclampsia S100A8/A9 Calgranulin 

Notes

Compliance with ethical standards

Funding

The authors report they did not receive funding for the present paper.

Conflict of interest

None for all authors.

Supplementary material

11_2015_903_MOESM1_ESM.doc (63 kb)
Supplementary material 1 (DOC 63 kb)

References

  1. 1.
    Ronsmans C, Graham WJ. Maternal mortality: who, when, where, and why. Lancet. 2006;368:1189–200.PubMedCrossRefGoogle Scholar
  2. 2.
    Thornton C, Dahlen H, Korda A, Hennessy A. The incidence of preeclampsia and eclampsia and associated maternal mortality in Australia from population-linked datasets: 2000–2008. Am J Obstet Gynecol. 2013;208(476):e1–5.PubMedGoogle Scholar
  3. 3.
    Lisonkova S, Sabr Y, Mayer C, Young C, Skoll A, Joseph KS. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol. 2014;124:771–81.PubMedCrossRefGoogle Scholar
  4. 4.
    Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013;209:544 e1–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Jelin AC, Cheng YW, Shaffer BL, Kaimal AJ, Little SE, Caughey AB. Early-onset preeclampsia and neonatal outcomes. J Matern Fetal Neonatal Med. 2010;23:389–92.PubMedCrossRefGoogle Scholar
  6. 6.
    Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv. 2011;66:497–506.PubMedCrossRefGoogle Scholar
  7. 7.
    Naljayan MV, Karumanchi SA. New developments in the pathogenesis of preeclampsia. Adv Chronic Kidney Dis. 2013;20:265–70.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014;10:466–80.PubMedCrossRefGoogle Scholar
  9. 9.
    Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda). 2009;24:147–58.CrossRefGoogle Scholar
  10. 10.
    Verdonk K, Visser W, Steegers EA, Kappers M, Danser AH, van den Meiracker AH. New insights into the pathogenesis of pre-eclampsia: the role of angiogenesis-inhibiting factors. Ned Tijdschr Geneeskd. 2011;155:A2946.PubMedGoogle Scholar
  11. 11.
    Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002;160:1405–23.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Sahay AS, Sundrani DP, Joshi SR. Regional changes of placental vascularization in preeclampsia: a review. IUBMB Life 2015.Google Scholar
  14. 14.
    Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol. 2013;94:247–57.PubMedCrossRefGoogle Scholar
  15. 15.
    Lok CA, Jebbink J, Nieuwland R, Faas MM, Boer K, Sturk A, et al. Leukocyte activation and circulating leukocyte-derived microparticles in preeclampsia. Am J Reprod Immunol. 2009;61:346–59.PubMedCrossRefGoogle Scholar
  16. 16.
    Mellembakken JR, Aukrust P, Olafsen MK, Ueland T, Hestdal K, Videm V. Activation of leukocytes during the uteroplacental passage in preeclampsia. Hypertension. 2002;39:155–60.PubMedCrossRefGoogle Scholar
  17. 17.
    Striz I, Trebichavs.ky I. Calprotectin—a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53:245–53.PubMedGoogle Scholar
  18. 18.
    Nilsen T, Sunde K, Larsson A. A new turbidimetric immunoassay for serum calprotectin for fully automatized clinical analysers. J Inflamm (Lond). 2015;12:45.CrossRefGoogle Scholar
  19. 19.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Wells GA, Shea B, O’Connel D, Peterson J, V W, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. www.ohri.ca/programs/clinical_epidemiology/oxford.asp, 2011.
  21. 21.
    Liosi S, Briana DD, Gourgiotis D, Boutsikou M, Baka S, Marmarinos A, et al. Calprotectin in human cord blood: relation to perinatal parameters and restricted fetal growth. J Perinat Med. 2010;38:523–6.PubMedGoogle Scholar
  22. 22.
    Staff AC, Braekke K, Johnsen GM, Karumanchi SA, Harsem NK. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol. 2007;197(176):e1–6.PubMedGoogle Scholar
  23. 23.
    Akcum S, Zulfikaroglu E, Eserdag S, Ozcan U. Plasma Calprotectin Levels in Preeclamptic Normotensive Pregnant and Nonpregnant Women. 2014.Google Scholar
  24. 24.
    Braekke K, Holthe MR, Harsem NK, Fagerhol MK, Staff AC. Calprotectin, a marker of inflammation, is elevated in the maternal but not in the fetal circulation in preeclampsia. Am J Obstet Gynecol. 2005;193:227–33.PubMedCrossRefGoogle Scholar
  25. 25.
    Sugulle M, Kvehaugen AS, Braekke K, Harsem NK, Staff AC. Plasma calprotectin as inflammation marker in pregnancies complicated by diabetes mellitus and superimposed preeclampsia. Pregnancy Hypertens. 2011;1:137–42.PubMedGoogle Scholar
  26. 26.
    Börekçi B, Aksoy H, Öztürk N, Kadanalı S. Correlation between calprotectin and oxidized LDL in preeclampsia. Turk J Med Sci. 2009;39:191–5.Google Scholar
  27. 27.
    Feng C, Tao Y, Shang T, Yu M. Calprotectin, RAGE and TNF-alpha in hypertensive disorders in pregnancy: expression and significance. Arch Gynecol Obstet. 2011;283:161–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Ramma W, Buhimschi IA, Zhao G, Dulay AT, Nayeri UA, Buhimschi CS, et al. The elevation in circulating anti-angiogenic factors is independent of markers of neutrophil activation in preeclampsia. Angiogenesis. 2012;15:333–40.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Zaid O, Abdel-Maksoud H, Elmagid A, Omnia M. Biochemical effect of pre eclampsia on serum calprotectin, ascorbic acid, Uric Acid and Calcium. Benha Veterinary Med J. 2014;27(2):217–24.Google Scholar
  30. 30.
    Holthe MR, Staff AC, Berge LN, Fagerhol MK, Lyberg T. Calprotectin plasma level is elevated in preeclampsia. Acta Obstet Gynecol Scand. 2005;84:151–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Ramma W, Buhimschi IA, Zhao G, Dulay AT, Nayeri UA, Buhimschi CS, et al. The elevation in circulating anti-angiogenic factors is independent of markers of neutrophil activation in preeclampsia. Angiogenesis. 2012;15:333–40.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Dale I, Brandtzaeg P, Fagerhol MK, Scott H. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am J Clin Pathol. 1985;84:24–34.PubMedGoogle Scholar
  33. 33.
    Brandtzaeg P, Dale I, Fagerhol MK. Distribution of a formalin-resistant myelomonocytic antigen (L1) in human tissues. I. Comparison with other leukocyte markers by paired immunofluorescence and immunoenzyme staining. Am J Clin Pathol. 1987;87:681–99.PubMedGoogle Scholar
  34. 34.
    Nakashige TG, Zhang B, Krebs C, Nolan EM. Human calprotectin is an iron-sequestering host-defense protein. Nat Chem Biol 2015.Google Scholar
  35. 35.
    Kerkhoff C, Klempt M, Sorg C. Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). Biochim Biophys Acta. 1998;1448:200–11.PubMedCrossRefGoogle Scholar
  36. 36.
    Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull. 2003;26:753–60.PubMedCrossRefGoogle Scholar
  37. 37.
    Espinoza J, Chaiworapongsa T, Romero R, Edwin S, Rathnasabapathy C, Gomez R, et al. Antimicrobial peptides in amniotic fluid: defensins, calprotectin and bacterial/permeability-increasing protein in patients with microbial invasion of the amniotic cavity, intra-amniotic inflammation, preterm labor and premature rupture of membranes. J Matern Fetal Neonatal Med. 2003;13:2–21.PubMedCrossRefGoogle Scholar
  38. 38.
    Buimer M, Keijser R, Jebbink JM, Wehkamp D, van Kampen AH, Boer K, et al. Seven placental transcripts characterize HELLP-syndrome. Placenta. 2008;29:444–53.PubMedCrossRefGoogle Scholar
  39. 39.
    Gallery ED, Campbell S, Arkell J, Nguyen M, Jackson CJ. Preeclamptic decidual microvascular endothelial cells express lower levels of matrix metalloproteinase-1 than normals. Microvasc Res. 1999;57:340–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Isaksen B, Fagerhol MK. Calprotectin inhibits matrix metalloproteinases by sequestration of zinc. Mol Pathol. 2001;54:289–92.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Bian Z, Shixia C, Duan T. First-trimester maternal serum levels of sFLT1, PGF and ADMA predict preeclampsia. PLoS One. 2015;10:e0124684.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing 2015

Authors and Affiliations

  • Vasilios Pergialiotis
    • 1
  • Anastasia Prodromidou
    • 1
  • Eleni Pappa
    • 1
  • Georgios D. Vlachos
    • 2
  • Despina N. Perrea
    • 1
  • Nikolaos Papantoniou
    • 3
  1. 1.Laboratory of Experimental Surgery and Surgical Research N.S. ChristeasNational and Kapodistrian University of AthensHalandriGreece
  2. 2.First Department of Obstetrics and Gynaecology, Alexandra HospitalNational and Kapodistrian University of AthensAthensGreece
  3. 3.Third Department of Obstetrics and Gynaecology, Attiko HospitalHospital, National and Kapodistrian University of AthensAthensGreece

Personalised recommendations